<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> or <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is a prominent feature of low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), although the underlying mechanism remains controversial </plain></SENT>
<SENT sid="1" pm="."><plain>High-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> have less <z:mpath ids='MPATH_3'>apoptosis</z:mpath> associated with increased expression of the prosurvival BCL2-related proteins </plain></SENT>
<SENT sid="2" pm="."><plain>To address the mechanism and pathogenic role of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and BCL2 expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we used a mouse model resembling human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, in which the fusion protein NUP98-HOXD13 (NHD13) of the chromosomal translocation t(2;11)(q31;p15) is expressed in hematopoietic cells </plain></SENT>
<SENT sid="3" pm="."><plain>Hematopoietic stem and progenitor cells from 3-month-old mice had increased rates of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> associated with increased cell cycling and DNA damage </plain></SENT>
<SENT sid="4" pm="."><plain>Gene expression profiling of these <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitors revealed a specific reduction in Bcl2 </plain></SENT>
<SENT sid="5" pm="."><plain>Restoration of Bcl2 expression by a BCL2 transgene blocked <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitors, which corrected the <z:hpo ids='HP_0001972'>macrocytic anemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Blocking <z:mpath ids='MPATH_3'>apoptosis</z:mpath> also restored cell-cycle quiescence and reduced DNA damage in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitors </plain></SENT>
<SENT sid="7" pm="."><plain>We expected that preventing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> would accelerate <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain>However, contrary to expectations, preventing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of premalignant cells abrogated transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast to the current dogma that overcoming <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is an important step toward <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, this work demonstrates that gaining a survival advantage of premalignant cells may delay or prevent leukemic progression </plain></SENT>
</text></document>